„How do we help patients around the world?”

Our novel technological platform solution unlocks the delivery of community-based infectious disease management. As stated by the World Health Organization (WHO) anti-microbial resistance is an increasingly serious threat to global public health that requires substantial focus and action across all aspects of society. Without effective antibiotics, the success of major surgery and cancer chemotherapy would be compromised. As the development of new molecules is challenging and very limited, it is of utmost importance to make better, more efficient, and safer use of existing antibiotics. Especially in terms of resistant microorganisms, existing oral and parenteral dosing schemes can be ineffective. Worst case this leads to death (even in more advanced health care systems the risk of death related to septicemia is up to 30%), but also to further spread in resistant organisms, making it a highly dangerous vicious circle.

For these reasons develops a medical device, that allows prolonged and continuous infusion, resulting in effective and safe dosing of antibiotics. Our innovative medical device eliminates the requirement for aseptic compounding and overcomes the problem of limited in-use stability of antibiotics for prolonged and continuous delivery.

Thanks to this revolutionary innovation, will not only simplify and improve the safety of current hospital infusion delivery management but will also accelerate and transform the access to outpatient parenteral antimicrobial therapy (OPAT). OPAT is a growing and necessary health care delivery system, driven by the need to reduce hospital-based costs. In addition, the existing hospitalization concepts need to be changed. As hospitals are an ideal breeding ground for superbugs, patients should be transferred once stable enough and thus as soon as possible to home-care treatment. 

The current OPAT system mainly relies on elastomeric infusion pumps, causing following disadvantages:

  • Poor stability of β-lactam antibiotics, once dissolved in liquid solutions
  • Onsite, expensive and error-prone compounding
  • Highly resource intensive due to frequent dosing

Hence, the existing system is not scalable and fails to provide full-scale OPAT. For convenience, physicians tend to select non-targeted antibiotics with less frequent dosing like ceftriaxone and this exacerbates the impact on the gut microbiome, increasing the risk of Clostridium difficile infection and thus propelling the emergence of drug-resistant organisms.

revIVe provides availability at scale allowing early discharge on IV-antibiotics, reducing in-patient costs, optimal use of healthcare resources, decreased risks of nosocomial infections and improved quality of life for patients.
Our medical device is not limited to anti-infectives’ treatment, but also represents the ideal solution for the parenteral delivery of drugs which are unstable in solution.